Drugs / Sagopilone
Sagopilone
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00432302 | Jan → Nov 2007 | neoplasm | Bayer | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00359359 | Jul 2006 → Mar 2009 | small cell lung carcinoma | Bayer | Completed | No outcome recorded |
| Phase 212 trials · 1 met primary · 4 missed | ||||||
| Phase 2 | NCT00751205 | Aug 2008 → Feb 2010 | ovarian carcinoma, prostate cancer | Bayer | Completed | Missed primary |
| Phase 2 | NCT00496379 | Jul 2007 → Oct 2009 | breast cancer, central nervous system disorder | Nancy Lin, MD | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00598507 | May 2007 → Jan 2013 | melanoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00424060 | Dec 2006 → Aug 2007 | central nervous system neoplasm | European Organisation for Research and Treatment of Cancer - EORTC | Completed | Missed primary |
| Phase 2 | NCT00325351 | Aug 2006 → Jul 2008 | ovarian neoplasm | Bayer | Completed | Met primary |
| Phase 2 | NCT00350051 | Aug 2006 → Sep 2008 | prostate cancer | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT00397072 | Jun 2006 → Mar 2008 | glioblastoma | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | Completed | No outcome recorded |
| Phase 2 | NCT00299390 | Apr 2006 → Apr 2007 | small cell lung carcinoma | Bayer | Terminated | No outcome recorded |
| Phase 2 | NCT00313248 | Apr 2006 → Oct 2008 | breast neoplasm | Bayer | Completed | Missed primary |
| Phase 2 | NCT00288249 | Dec 2005 → Mar 2008 | breast cancer | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT00246688 | Nov 2005 → Jun 2007 | ovarian cancer | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT00160069 | Aug 2005 → Apr 2008 | non-small cell lung carcinoma | Bayer | Completed | Missed primary |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sagopilone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00424060 ↗ |
| Known as | BAY86-5302 | “Drug: Sagopilone (BAY86-5302, ZK 219477)” NCT00288249 ↗4“Drug: Sagopilone (BAY86-5302, ZK 219477)” NCT00359359 ↗ “Sagopilone (BAY 86-5302, ZK 219477)” NCT00432302 ↗ “Sagopilone (BAY86-5302, ZK 219477)” NCT00299390 ↗ “Sagopilone (BAY86-5302, ZK 219477)” NCT00160069 ↗ |
| Known as | DE-03757 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2304041 ↗ |
| Known as | SAG | “Peripheral neuropathy (PN) is a recognized side effect of microtubule-targeting agents and the most clinically relevant toxicity observed with the epothilone sagopilone (SAG).” PMID 24105751 ↗ Oct 2013 |
| Known as | Sagopilona | ChEMBL registry synonym — accepted as the source's own label CHEMBL2304041 ↗ |
| Known as | ZK 219477 | “Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma.” PMID 21321091 ↗ Feb 20119“Drug: Sagopilone (BAY86-5302, ZK 219477)” NCT00288249 ↗ “Drug: Sagopilone (BAY86-5302, ZK 219477)” NCT00359359 ↗ “Sagopilone (BAY 86-5302, ZK 219477)” NCT00432302 ↗ “Sagopilone (ZK 219477) + prednisone” NCT00350051 ↗ “Sagopilone (BAY86-5302, ZK 219477)” NCT00160069 ↗ “Sagopilone (BAY86-5302, ZK 219477)” NCT00299390 ↗ “Sagopilone (ZK 219477)” NCT00313248 ↗ |
| Known as | ZK-EPO | “A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer.” PMID 21372124 ↗ Mar 2011 |
| Action | Inhibit | “ZK 219477 inhibits microtubule depolymerization, causing cell cycle blockage in G2/M phase and induction to apoptosis.” NCT00397072 ↗ |
| Modality | Small molecule | “Sagopilone is the first fully synthetic epothilone in clinical development” PMID 23522488 ↗ Mar 2013 |
| Route | Intravenous | “i.v. infusion” NCT00246688 ↗ |